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Abstract
In patients with chronic disorders, control self-efficacy is the confidence with managing
symptoms and coping with the demands of illness. Can do treatment (CDT) is an intensive,
3-day, social cognitive theory-based, multidisciplinary treatment that focuses on identifica-
tion of stressors, goal setting, exploration of boundaries, and establishment of new bound-
aries. An uncontrolled study showed that patients with relapsing remitting multiple sclerosis
(RRMS) and low-disability had improved control self-efficacy six months after CDT. Hence,
in a 6-month, single-centre, randomized (1:1), unmasked, controlled trial in RRMS patients
with Expanded Disability Status Scale (EDSS) score�4.0, we compared CDT with no inter-
vention and the option to receive CDT after completion of study participation. Follow-up
assessments were at one, three and six months. Primary endpoint was control self-efficacy
(Multiple Sclerosis Self-Efficacy Scale Control [MSSES-C] (minimum 90, maximum 900) at
six months. Secondary endpoints were functional self-efficacy (MSSES-F), participation
and autonomy (Impact on Participation and Autonomy questionnaire [IPA]), health-related
quality of life (MS Quality of Life-54 Items questionnaire [MSQoL-54]), anxiety, depression
(Hospital Anxiety and Depression Scale [HADS]) and coping skills (Utrecht Coping List
[UCL]) at six months. Tertiary endpoint was care-related strain on support partners
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(Caregiver Strain Index) at six months. Of the 158 patients that were included, 79 were
assigned to CDT and 79 to the control group. Two CDT patients discontinued treatment pre-
maturely. Sixty-one (77%) control patients chose to receive CDT after study participation.
Intention-to-treat ANCOVA analyses were performed with follow-up values as dependent,
and condition, baseline values, disease duration and gender as independent variables. The
mean (standard deviation [SD]) MSSES-C score in the CDT group vs. control group at base-
line was 468 (162) vs. 477 (136), and at six months 578 (166) vs. 540 (135) (p = 0.100). Sec-
ondary and tertiary endpoints did not differ between groups, except for the UCL palliative
reaction score being slightly higher in the CDT group (p = 0.039). On post hoc analyses the
MSSES-C score at one and three months was higher in the CDT vs. control group: 597
(114) vs. 491 (131) (p<0.0001) and 561 (160) vs. 514 (143) (p = 0.018), respectively; and at
one month the MSSES-F, IPA Limitations, HADS Anxiety and Depression, and MSQoL-54
Mental and Physical scores were also in favour of the CDT group. We conclude that in low-
disability RRMS patients, the intensive 3-day social cognitive theory-based CDT did not
improve control self-efficacy at six months follow-up compared to waitlist controls. The
absence of a between-group difference at six months relates to a gradual improvement in
the control group. In all, this social cognitive theory-based approach for improving self-effi-
cacy needs further investigation before being broadly applied in RRMS patients.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and degenerative disease of
the central nervous system. Intermittent or continuous disease activity frequently results in a
stepwise or slow increase in disabilities. The disease course is largely unpredictable, as is the
response to disease-modifying drug treatment. It is therefore unsurprising that, due to experi-
ences of disappearing abilities and the uncertainty regarding their future, MS patients may lose
their self-confidence.
Self-efficacy is a psychological concept that refers to the degree to which a person is confi-
dent to be able to complete tasks and reach goals in specific situations [1]. It is a core compo-
nent in social cognitive theory, according to which psychosocial functioning is determined by
reciprocal interactions between personal factors, behavior and the environment. Self-efficacy
is a strong predictor of health behavior, and it can be instrumental in modulating the experi-
ence of chronic illness. In MS patients low self-efficacy is associated with lower health-related
quality of life (HRQoL) [2], less mood control [3], less social activity [3] and less physical activ-
ity [4]. In recent years various interventions have been developed aiming to increase self-effi-
cacy in patients with MS. However, evidence form randomized controlled trials (RCT) for the
effectiveness of these approaches is scarce and variable [5–8].
We previously reported findings from an observational study on self-efficacy in MS patients
after can do treatment (CDT), an intensive 3-day multidisciplinary social cognitive theory-
based intervention [9]. Six months after CDT, patients with relapsing remitting (RR) MS and
those with low disability (Expanded Disability Status Scale [EDSS] score<4.0) showed an
improvement of control self-efficacy, i.e. improved confidence in managing symptoms and
coping with the demands of illness [9].
In view of these findings we performed in low-disability RRMS patients a 6-month, single-
centre, unmasked RCT to investigate the effect of CDT on control self-efficacy, with control
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participation. The primary outcome was the between-group difference at six months. Our




Concept. CDT is a social cognitive theory-based intervention aiming to uncover and pro-
mote existing capabilities, with the notion ‘stressor’ as central concept [9]. CDT is based on the
identification and reduction of stressors; client-centeredness; potential inclusion of partner or
another significant informal caregiver; group sessions; and self-reliance, autonomy and accep-
tance as central themes [9]. CDT focuses on the exploration of those stressors that confine
patients to their physical, psychological or social roles regarding their disease and limitations;
reduces relevant stressors; explores and pushes personal boundaries; and creates new personal
boundaries by making optimal use of the existing potential [9]. To place the individual’s capa-
bilities in a realistic framework, CDT’s central themes are ‘Can’, ‘Will’, ‘Choose’, ‘Open up to
others’, and ‘Do’. CDT hypothesizes that by exploring their boundaries patients become more
aware of their faculties, and that the higher awareness of potentials leads to self-management
[9].
Components. CDT’s components are large group sessions, small group sessions, consul-
tations (carrousel), a theatre evening, and start of the day with a joint activity (optional) [9].
Large group sessions include plenary sessions–where participants make optimal use of their
existing potentials, learn how to support and encourage other participants, and experiment
how to give the required feedback to the multidisciplinary team—, and group sessions in
which half of the participants take part–where they examine and identify which stressors have
to be addressed most, and formulate one or two realizable individual aims [9].
After having identified and formulated individual stressors and aims, participants sign in
for one or more group consultations, during which they verify whether their aims are realiz-
able by asking the members of the multidisciplinary team for aim-related medical information
[9].
Small group sessions form the actual training [9]. Depending on their individual goals the
participants sign up for the training groups ‘Body’, ‘Feeling’ or ‘Life’, to work out their aims
and to experiment whether they can reduce their stressors. Body sessions focus on the explora-
tion of physical capabilities and are coached by a physiotherapist. Feeling sessions focus on the
exploration of the emotional potential and are coached by a psychiatrist and a psychiatric
nurse. Life sessions focus on the exploration of capabilities relating to daily living with MS and
are coached by a neurologist, a registered nurse specialized in MS, and a person with MS. In
addition, there are relaxation sessions for those who have difficulties in experiencing their
body: dance sessions focus on body experience and relaxation, and make participants aware of
the relationship between physical sensations and their emotions and feelings, whereas physical
sessions focus on relaxation through physical strain. Participants autonomously chose between
the various small group sessions without being influenced by team members [9].
On the informal theatre evening the participants practice to change roles and to show their
potentials by openly experimenting. They do their best to perform before each other and the
team. The jointly created evening performance increases the cohesion within the group and
learns participants to find an equilibrium between consuming and action [9].
During an optional joint activity (walk in the woods) at the start of the day the participants
experiment with physical challenges and with the management of their energy [9].
Effect of social cognitive treatment on control self-efficacy in multiple sclerosis
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Multidisciplinary team. The multidisciplinary team included a psychiatrist, psychiatric
nurse, neurologist, registered nurse specialized in MS, physiotherapist, dance therapist, and a
person with MS [9]. All professional team members were formally trained in their respective
disciplines and all members were experienced in the field of MS. The person with MS had
experience with chronic symptoms and multiple disease-modifying treatments. As the team
members were also involved in the preceding observational study—except for the dance thera-
pist -, the team was experienced in providing CDT [9]. Before starting the first CDT of the
observational study, team members held two plenary sessions, in which the psychiatrist and
psychiatric nurse informed the other members about this social cognitive theory-based
approach, and during which the team became familiar with the concept, and each team mem-
ber’s specific contribution to CDT.
The members respected and understood the participants’ individual qualities and differ-
ences, and they stimulated, defied and confronted them to explore and push their boundaries
[9]. Apart from the consultations the team kept to coaching, stimulating and activating the
participants. By participating in the large group sessions team members became familiar with
the participants’ individual stressors and goals. During the consultations they had a profes-
sional and informative role. In the small group sessions every team member focused on its
own area of interest. During a tip time at the end of each day the team members evaluated the
sessions, informed each other on the participants’ progresses and obstacles, discussed whether
the participants made optimal use of their opportunities, monitored to what extent the per-
sonal goals were being attained, and noted adverse events [9]. At the end of the intervention
any premature discontinuations were documented.
Study design and participants
We did a single-centre, randomized (1:1), unmasked, parallel-group, controlled trial in the
Netherlands. The first version of the study protocol (September 2012) has been extended with
an economic evaluation, the Utrecht Coping List (UCL), and information about financial
aspects and randomization procedure (amended version March 2013). The ethics approval
was obtained on February 11, 2013 from the ethical committee Medisch Ethische Toetsing
Onderzoek Patiënten en Proefpersonen, Tilburg, the Netherlands. Medische Ethische Toetsing
Commissie (METC) number 499; NL number: NL4220502812. Dutch Trial Registry: Trial
NL5158 (NTR5298) (https://www.trialregister.nl/trial/5158). Due to a miscommunication
between the MS4 Research Institute, Nijmegen, the Netherlands, and the National Multiple
Sclerosis Foundation (NMSF), Rotterdam, the Netherlands, the trial was registered after the
inclusion had started, namely July 10, 2015. The authors confirm that all ongoing and related
trials for this intervention are registered. The study protocol has been published May 28, 2016,
including an adapted statistical section, as we considered the 6-month outcome more informa-
tive and clinically relevant than the mean of the 3-month and 6-month values [10] (https://
bmcneurol.biomedcentral.com/articles/10.1186/s12883-016-0593-4).
The study population was low-disability RRMS patients with or without support partner.
Eligibility criteria for patients: diagnosis RRMS since at least one year, EDSS score�4.0, no
symptoms suggestive of a relapse, no relapse in the preceding four weeks, willing and capable
of participating in the investigations, and having access to the internet for performing the
web-based assessments. Eligibility criteria for support partners: willing and capable of partici-
pating in the investigations, and having access to the internet.
Participants were recruited from all over the Netherlands by the patient organisation
NMSF, Rotterdam, the Netherlands. Interested patients were contacted by a registered nurse
experienced in MS (MH) by phone to check diagnosis and eligibility criteria. The MS diagnosis
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was not confirmed by a neurologist. The criterion of EDSS�4.0 was checked by assessing
whether the patient was self-sufficient and able to walk�500 meters without aid or rest [11].
In addition, to assess the degree of disability, the EDSS score was further quantified on-site by
an experienced neurologist, prior to the start of CDT, in patients randomized to the interven-
tion; and in those control patients who chose to receive CDT after study completion.
The enrolment started February 2013 and ended April 2016. The follow-up started April
2013 (first 1-month assessment) and ended December 2016 (last 6-month assessment).
Patients and support partners gave their written informed consent. CDT was given during
three consecutive days in Zorghotel Spelderholt, Beekbergen, the Netherlands, a facility espe-
cially equipped for the accommodation of people with impaired health. The number of ses-
sions, their schedule, and their duration are presented in the Appendix (see App 1).
Randomization
Patients were randomized in a 1:1 ratio to CDT or control group via stratified block randomi-
zation with disease duration and gender as blocking factors using block sizes of four. Patients
randomized into the control group received any care or treatments that were deemed neces-
sary by caregivers, and were given the opportunity to receive CDT after study completion of
study participation. The sequence with which participants were allocated was generated at the
Department for Health Evidence, Radboud university medical centre, Nijmegen, the Nether-
lands (RD). Patients were enrolled by the NMSF (MH). An independent statistician who had
no involvement in the rest of the trial assigned the patients to the trial groups. Participants, the
multidisciplinary team, those assessing the outcomes, and those analysing the data were not
masked to group assignment.
Outcomes and assessments
Primary outcome. The primary study outcome was the change in control self-efficacy,
assessed by the Multiple Sclerosis Self-Efficacy Scale (MSSES), at six months [12]. The MSSES
is a specific and sensitive self-report questionnaire consisting of two 9-items subscales for con-
trol and functional self-efficacy, with a high internal consistency and test-retest reliability [12].
Each item is scored from 10 (very uncertain) to 100 (very certain), and addition of the item
scores yields the MSSES Control (MSSES-C) and Function (MSSES-F) scores (minimum 90,
maximum 900). The MSSES-C measures confidence with managing symptoms and coping
with the demands of illness, and the MSSES-F measures confidence with regard to functional
abilities [12].
Secondary outcomes. Secondary endpoints were changes in functional self-efficacy
(MSSES-F), participation and autonomy, HRQoL, anxiety, depression and coping styles at six
months.
Participation and autonomy were assessed by the Impact on Participation and Autonomy
(IPA) questionnaire [13]. The IPA-Limitations subscale assesses perceived limitations in par-
ticipation and autonomy, and a higher score indicates higher limitations to participation and
autonomy. The IPA-Problems subscale examines the extent to which these limitations are
experienced as problematic, and a higher IPA-Problems score indicates a greater experience of
problems [13].
HRQoL was assessed via the Multiple Sclerosis Quality of Life 54-Items (MSQoL-54) [14].
The MSQoL-54 is an MS-specific, multi-dimensional inventory of patient-centered health
status, and consists of the Short Form 36-Items health survey as a generic core measure, sup-
plemented with 18 questions on items relevant to patients with MS. A physical and a mental
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dimension underlie the MSQoL-54: the physical and mental domains [14]. Scores for each
domain range from 0–100, where higher values indicate better HRQoL.
Anxiety and depression were measured by the Hospital Anxiety and Depression Scale
(HADS), which is a 14-item, self-report questionnaire consisting of two subscales for anxiety
and depression [15]. A total subscale score of eight to 10 points indicates possible mild to mod-
erate symptoms of anxiety/depression, and 11 to 21 points indicate a probable clinically signifi-
cant condition of anxiety/depression [15].
Coping styles were assessed with the Utrecht Coping List (UCL) [16]. The scores on the
subscales ‘palliative reaction’ and ‘avoidance’ range from eight to 32, the scores on the sub-
scales ‘active tackling’ and ‘passive reaction’ range from seven to 28, and the scores on the sub-
scales ‘emotion expression’, ‘comforting cognitions’ and ‘social support’ range from three to
12, five to 20 and from six to 24, respectively.
Tertiary outcome. The tertiary endpoint was change in care-related strain on support
partners at six months, which was assessed by the Caregiver Strain Index (CSI) [17]. The CSI
includes thirteen items yielding a total score between zero and 13. A higher score indicates
higher care-related strain, and scores of seven or higher are associated with caregivers’ self-
reports of experiencing situations that conflict with giving help [17].
Assessment schedule. Assessments were at baseline and at one, three and six months fol-
low-up via online questionnaires (www.ms4ri.nl). Data were acquired with use of the open
source online application LimeSurvey1 in compliance with European Union regulations con-
cerning online medical data. For patients the completion of the questionnaires took about 45
minutes and for partners about five minutes per time point.
Safety and adverse events assessment. During CDT, safety aspects and adverse events
were assessed and documented by the multidisciplinary team at the end of each day. After hav-
ing completed CDT, participants were informed to contact the help desk of the NMSF or the
psychiatrist of the team (RPR) in case of questions or complaints.
Statistical aspects
The sample size calculation was based on the difference in MSSES-C score between baseline
and six months in low-disability RRMS patients in the observational study [9]. We assumed at
six months an average MSSES-C score of 650 for the CDT group and of 560 for the control
group. Assuming a standard deviation (SD) of 200 at the 6-month measurement, 79 patients
were needed per group to obtain a power of 80%, using a two-sided t-test with an alpha of 5%.
However, as we used the baseline measurement in the analysis, this number had to be multi-
plied by a design factor equalling 1 –r2 baseline, 6 months. Assuming a correlation of 0.5,
based on the observational data, this design factor equals 0.75. Therefore, the number of ana-
lyzable patients needed to obtain a power of 80% equalled approximately 60 per group. Taking
into account an expected drop-out of at least 15% we aimed to include a minimum of 140
patients.
All endpoints were analyzed according to the intention-to-treat principle using an
ANCOVA with the 6-month value as dependent variable, and condition, baseline value, dis-
ease duration and gender as independent variables. Hedges’ g was used to calculate the effect
size for the primary outcome in order to understand the effect of the intervention.
Post hoc analyses included ANCOVA with the 1-month and 3-month values as dependent
variables, and condition, baseline values, disease duration and gender as independent vari-
ables; multiple regression analysis to detect the contribution of age, gender, disease duration,
EDSS score and education at six months, and using graphical inspection of the residuals to
check whether the assumptions of the analysis model were fulfilled; related-samples Wilcoxon
Effect of social cognitive treatment on control self-efficacy in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0223482 October 10, 2019 6 / 14
signed rank tests for within-group comparisons of follow-up versus baseline; and Χ2-tests to
compare ‘early permanent responders’ (i.e. improved control self-efficacy at both one and six
months), ‘delayed responders’ (i.e. improvement at six months but not at one month), and
‘early non-permanent responders’ (i.e. improvement at one but not at six months), whereby
improvement was defined as an increase of at least 75 points compared to baseline, being�0.5
SD baseline (n = 155). Moreover, at each follow-up time point we calculated for every patient
the percentage change in MSSES-C from baseline, added the respective percentages, and
divided the sum by the number of observations, resulting in a mean percentage change from
baseline per time point.
The analyses were performed at the Department of Health Services Research, Care and
Public Health Research Institute, Maastricht University, Maastricht, the Netherlands (GAvM)
and the Department for Health Evidence, Radboud university medical centre, Nijmegen, the
Netherlands (RD). The statistics program used was Statistical Package for the Social Sciences
(IBM Corporation, Armank, U.S.A.) for Windows version 24. In all analyses p-values < 0.05
were considered statistically significant. Analyses beyond the primary outcome were explor-
atory, and therefore the type I error rate was not strictly controlled.
Results
A total of 272 patients were screened for eligibility (Fig 1). Of the 194 eligible patients, 36
decided not to participate, 79 were assigned to CDT, and 79 to the control group (Fig 1). The
full analysis set (intention-to-treat population) for the primary outcome comprised 158
patients.
The baseline demographic and disease characteristics of the intention-to-treat population
are presented in Table 1.
CDTs were given between April 5, 2013 and May 29, 2016. In the CDT group 61 (77.2%)
patients participated with support partner, and in the control group 47 (59.5%). The interven-
tion was delivered as planned in all patients except for two (2.5%) patients, who discontinued
CDT prematurely. Follow-up data at 1, 3 and 6 months were not available for 11 (14%), 15
(19%) and 22 (28%) CDT patients, and for 12 (15%), 4 (5%) and 16 (20%) control patients,
respectively (Fig 1).
Pre-specified analyses
The baseline and follow-up values for the primary, secondary and tertiary outcomes in both
groups, and the between-group differences at follow-up are presented in Table 2. At six
months the MSSES-C score did not statistically significantly differ between the two groups.
The mean (SD) score in the CDT group was 578 (166) and in the control group 540 (135) (Fig
2, Table 2), and the mean (95%Confidence Interval [CI]) between-group difference was 18 (-8,
88) (p = 0.100). The MSSES-C effect size at six months was .25, indicating a small effect of
CDT.
As to the secondary and tertiary endpoints, at six months the UCL palliative reaction score
was slightly higher in the CDT group ([0.1,2.0], p = 0.039), while the other outcomes showed
no between-group differences (Table 2).
Post hoc analyses
Multiple regression analysis with age, gender, disease duration, EDSS score and education as
independent variables and MSSES-C at six months as a dependent variable showed no associa-
tions. At six months, 31 of 54 (57.4%) CDT patients and 26 of 56 (46.4%) control patients had
an improved control self-efficacy, whereby improvement was defined as an increase of at least
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75 points compared to baseline, being�0.5 SD baseline (n = 155). ANCOVA analyses showed
that at one and three months the mean (95%CI) between-group difference in MSSES-C score was
108 (75,146) (p = .000) and 45 (10,100) (p = .018), respectively, in favour of the CDT group
(Table 2). As to within-group comparisons, at all three follow-up time points, and in both the
CDT and the control group, the MSSES-C score was higher than at baseline (all p-values>.001).
Actually, at one, three and six months the mean (SD) change in MSSES-C score from baseline
was +54.0% (92.7%), +38.5% (89.1%) and +42.6% (91.4%) in the CDT group and +10.4%
(41.8%), +13.8% (45.9%) and +24.8% (47.9%) in the control group. In the CDT group 29 of 54
(53.7%) patients of whom the one and six month values were available, were early ‘permanent
responders’, and in the control group 11 of 56 (19.6%) patients (p = 0.000; Χ2-test). The frequency
of ‘delayed responders’ (n = 3 in CDT vs. n = 15 in control) and of ‘early non-permanent respond-
ers’ (n = 4 in CDT vs. n = 4 in control) did not differ between the groups (both p = 0.077, Χ2-test).
As to the secondary and tertiary endpoints, at three months the IPA Limitations score was
lower in the CDT group than in the control group (p = 0.011) (Table 2), and at one month the
MSSES-F, IPA Limitations, HADS Anxiety and Depression, mental and physical MSQoL-54,
and UCL active tackling, palliative reaction, social support, and passive reaction scores
favoured the CDT group (Table 2).
Fig 1. Patient flow diagram.
https://doi.org/10.1371/journal.pone.0223482.g001
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Safety and adverse events
No safety concerns or adverse events were noted during the intervention. Moreover, the fol-
low-up HADS data did not suggest that an increase in depressive symptoms or anxiety
occurred more frequently in patients in the CDT group than in the control group (Table 2).
However, the two patients who had prematurely discontinued CDT, contacted the NMSF after
the intervention with complaints: one patient (female, 44 years, disease duration 24 years)
stated that the treatment did not meet her expectations, and one patient (female, 38 years, dis-
ease duration 10 years) stated that the psychiatrist was too confronting and that the treatment
was damaging.
Table 1. Demographic and disease characteristics of the intention-to-treat population.
CDT (n = 79) control (n = 79)
Age, years (n = 77)
Mean (SD) 40 (8.7) 40 (9.4)
Median (range) 41 (20–61) 40 (23–61)
Gender, n (%)
Women 69 (87.3%) 70 (88.6%)
Men 10 (12.7%) 9 (11.7%)
Living situation, n (%) (n = 75) (n = 73)
Alone 16 (23.0%) 15 (19.0%)
With one or more people 59 (74.6%) 58 (73.3%)
Marital status, n (%) (n = 75) (n = 73)
Living together, married 50 (66.3%) 44 (55.7%)
Single 19 (22.4%) 18 (22.8%)
Divorced 5 (6.3%) 7 (8.9%)
Other 1 (1.3%) 4 (5.1%)
Education, n (%) (n = 75) (n = 73)
Primary school or lower education 2 (2.5%) 3 (3.8%)
Middle education 26 (33.0%) 31 (39.3%)
Higher education 47 (59.5%) 39 (49.4%)
Work status, n (%)
Employed, including self-employed 26 (32.9%) 37 (46.9%)
Disabled 35 (44.3%) 34 (43.0%)
Sick leave 19 (24.1%) 18 (22.8%)
Voluntary work 21 (26.6%) 16 (12.3%)
Applicant for job 17 (21.5%) 5 (6.3%)
Other (student, retired) 11 (14.0%) 4 (5.1%)
EDSS (n = 78) (n = 52)
Mean (SD) 2.3 (1.03) 2.3 (1.13)�
Median (range) 2.5 (0–4) 2.5 (0–4.5)
Time since diagnosis, years (n = 78)
Mean (SD) 6.5 (5.6) 6.5 (5.3)
Median (range) 5 (0–25) 5 (1–21)
Self-reported health disorders, n (%)
No 69 (87.3%) 64 (81.0%)
Yes 6 (7.6%) 9 (11.4%)
CDT: Can do treatment; SD: standard deviation; EDSS: Expanded Disability Status Scale; �, assessed at six months.
https://doi.org/10.1371/journal.pone.0223482.t001
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Discussion
Principal findings
This RCT investigated the effect of CDT, an intensive 3-day multidisciplinary social cognitive
theory-based intervention, on control self-efficacy in low-disability RRMS patients. The
MSSES-C score at six months—the trial’s primary endpoint—did not differ between the inter-
vention and control groups. However, at one and three months the MSSES-C score was higher
in CDT than control patients.
Findings in context
Only few RCTs investigating the effect of social cognitive approaches on self-efficacy in RRMS
have been reported. Three RCTs in US American patients on physical activity were negative
with respect to exercise self-efficacy—which was in all studies a secondary outcome [5–7].
Recently, a RCT in 91 MS patients– 86% RRMS and the majority experiencing mild to
Table 2. Baseline and follow-up outcomes in the CDT (n = 79) and control (n = 79) groups, and between-group differences at follow-up.
Baseline One month Three months Six months






















.000 [75,146] 514 (143) 561
(160)
.018 [10,100] 540 (135) 578
(166)
.100 [–8,88]
MSSES0-Function 701 (93) 693
(113)
691 (95) 724 (89) .002 [14,64] 697 (107) 706
(137)
.582 [–28,49] 711 (79) 703
(116)
.765 [–38,28]
IP Limitations 1.5 (0.6) 1.6 (0.6) 1.5 (0.6) 1.3 (0.6) .000 [-.4,-0.2] 1.5 (0.7) 1.4 (0.7) .011 [-0.4,-
0.0]
1.4 (0.7) 1.3 (0.7) .329 [-0.3,1.0]
IPA Problems 1.0 (0.5) 1.1 (0.5) 1.1 (0.5) 1.0 (0.5) .103 [-.2,0.2] 1.1 (0.5) 1.0 (0.6) .048 [-0.3,-
0.0]





































HADS Anxiety 7.7 (4.4) 8.4 (4.0) 7.5 (4.4) 6.5 (3.9) .000 [-2.5,-
0.7]
6.7 (4.1) 6.8 (4.1) .370 [-1.5,0.6] 6.6 (4.3) 6.5 (4.3) .506 [-1.4,0.7]
HADS Depression 6.3 (4.2) 6.4 (3.6) 6.3 (4.1) 5.0 (3.8) .008 [-2.1,-
0.3]
5.9 (4.5) 5.3 (3.8) .131 [-1.8,0.2] 5.1 (4.0) 5.2 (4.1) .623 [-0.8,1.2]
UCL Active
tackling
18.3 (4.2) 17.4 (4.3) 17.5 (3.9) 18.9 (3.8) .000 [1.1,2.8] 18.5 (4.3) 18.6 (3.8) .101 [-0.1,1.5] 18.4 (4.2) 18.7 (4.0) .277 [-0.5,1.6]
UCL Palliative 18.3 (3.6) 17.6 (3.6) 17.6 (3.8) 17.6 (3.5) .032 [0.1,1.8] 17.9 (3.6) 17.9 (3.8) .078 [-0.1,1.8] 17.7 (3.8) 17.8 (3.7) .039 [0.1,2.0]
UCL Avoidance 17.2 (3.7) 17.0 (3.4) 16.9 (3.7) 16.8 (3.3) .925 [-0.8,0.9] 16.2 (3.4) 17.1 (3.3) .054 [-0.0,1.9] 16.8 (3.3) 17.4 (3.3) .054 [-0.0,2.0]
UCL Social
support
13.5 (4.3) 13.2 (4.2) 13.1 (4.3) 13.7 (3.8) .003 [0.5,2.1] 13.9 (4.2) 14.0 (3.9) .293 [-0.4,1.4] 13.6 (4.6) 13.6 (4.0) .923 [-1.0,1.1]
UCL Passive 13.0 (3.5) 13.2 (3.2) 12.9 (3.7) 11.9 (3.3) .006 [-1.8,-
0.3]
12.3 (3.8) 12.3 (3.2) .562 [-1.0,0.5] 12.2 (3.9) 12.6 (4.0) .275 [-0.4,1.5]
UCL Emotion 6.0 (1.7) 6.4 (1.9) 6.1 (1.7) 5.9 (1.4) .097 [-0.8,0.1] 5.9 (1.7) 6.0 (1.9) .825 [-0.4,0.5] 6.1 (1.8) 5.9 (1.5) .538 [-0.6,0.3]
UCL Comforting 12.6 (2.7) 12.7 (2.9) 12.5 (2.6) 12.7 (2.6) .608 [-0.5,0.9] 12.3 (2.6) 12.4 (2.9) .728 [-0.6,0.9] 12.4 (2.7) 12.5 (3.0) .782 [-0.7,0.9]
CSI�� 4.6 (2.8) 5.1 (3.0) 4.6 (3.1) 4.4 (2.6) .176 [-1.3,0.2] 4.7 (2.9) 4.4 (2.8) .182 [-1.3,0.3] 4.7 (3.0) 5.0 (3.2) .724 [-1.2,0.8]
CDT: can do treatment; MSSES: Multiple Sclerosis Self-Efficacy Scale; SD: standard deviation; IPA: Impact on Participation and Autonomy; MSQoL-54: Multiple
Sclerosis Quality of Life-54 Items questionnaire; HADS: Hospital Anxiety and Depression Scale; UCL: Utrecht Coping List; CSI: Caregiver Strain Index
�ANCOVA (see Methods)
�� partners of MS patients.
https://doi.org/10.1371/journal.pone.0223482.t002
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moderate disability—found that a 12-wk educational socialization program resulted in
improved self-efficacy compared with control group participants [8]. Notably, various features
distinguish our study from these RCTs, such as the role of a patient organisation in study initi-
ation, funding, patient recruitment and data collection; the direct-to-patient recruitment pro-
cedure; and the large, representative sample size.
Despite an evident improvement of control self-efficacy in the CDT group at six months, the
difference with the controls was not statistically significant. Interestingly, we observed an early
improvement (one month) after CDT, but not in the controls; and, while the improvement in the
CDT group was largely maintained at six months, the control group improved gradually over
time (Fig 2). The change in the control patients was unexpected, for, in a 30-month prospective
longitudinal study in RRMS, exercise self-efficacy did not change throughout the whole study
period [18]; and a recent study in twins, investigating the causal structure of general self-efficacy
in young people, found that 75% of variation in self-efficacy was due to genetic factors [19].
The improvement in the control group could be related to various factors. First, we used a
waitlist control, and 61 (77%) of the control patients did indeed chose to receive CDT after the
study. It has been known that waitlist control groups may behave in different and unpredict-
able ways. Thus, an exploratory RCT evaluating the impact of a waitlist control design,
reported that in persons with problem drinking–a chronic health condition–the outcomes had
improved by 25–35% after four weeks in the waitlist group [20]. So, in our controls the pros-
pect of eventually receiving CDT may have elicited positive expectations that led to the antici-
pation of the desired effect. Second, study procedures could have played a role, like the
repeated completion of questionnaires or the personal contact during the eligibility assessment
by phone [21]. Third, people build their self-efficacy by observing successful efforts made by
others and by verbal persuasion that one is capable of managing one’s challenges [1]. During
Fig 2. Mean (bars) and SD (whiskers) values of MSSES Control scores (minimum 90, maximum 900) at baseline and at one, three and six months follow-up in
CDT and control groups. SD: standard deviation; MSSES: Multiple Sclerosis Self-Efficacy Scale; CDT: can do treatment.
https://doi.org/10.1371/journal.pone.0223482.g002
Effect of social cognitive treatment on control self-efficacy in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0223482 October 10, 2019 11 / 14
the 3-year period from first-patient-in to last-patient-out, control patients may have commu-
nicated with participants who reportedly benefited from CDT, and may thus have become
convinced of CDT’s impact. Importantly, the increased use of social media in recent years is
likely to have facilitated such communication. Moreover, to promote recruitment, the NMSF
actively communicated the potential benefits of CDT via folders and in the media. Fourth,
patients were free to receive outside of the study any care that was deemed necessary, and most
patients did receive at least some psychological, psychotherapeutic, psychiatric or social-psy-
chiatric nursing care; however, the amount of care was low, and there were no differences
between control and CDT patients (data not shown).
An economic evaluation was attached to this RCT, which assessed from a societal perspec-
tive the cost-effectiveness of the intervention [22]. When using the EuroQol-5 Dimensions-5
Levels questionnaire to calculate a quality-adjusted-life-year, CDT was not cost-effective.
However, when using the MSSES-C or Short Form-6 Dimensions (part of the MSQoL-54) as
outcomes, there is a probability that CDT is cost-effective [22].
Strengths and limitations
The study has several strengths, such as the large sample size of 158 patients, and the recruit-
ment of patients from all over the Netherlands. Moreover, the number of patients who were
not treated according to the protocol was low, and the analysis of the data was performed by
independent researchers who were not otherwise involved in the trial. Importantly, the follow-
up was longer than in other RCTs on self-efficacy. E.g. in a recent report by Kalina et al. on the
positive effect of a 12-week educational socialization programme on self-efficacy in MS, the
post-treatment assessment was scheduled immediately after the programme’s completion [8].
On the other hand, the study has several limitations. First, the follow up may have been too
short to assess the full effects of CDT, as a recent observational study showed improved anxiety
and depression 12 months after the intervention, in addition to improved control self-efficacy
[23]. Second, the direct-to-patient design and the role of the patient organization may have led
to biased or partial information or unwanted interactions between participants. Third, while
in the observational study all patients participated with a support partner, in this study about
one third of the patients were unaccompanied, which might have interfered with the full devel-
opment of the CDT’s effects.
Conclusions
An unmasked RCT assessed the effect of CDT, an intensive 3-day multidisciplinary social cog-
nitive theory-based treatment, on control self-efficacy in low-disability RRMS patients and
found no difference compared with waitlist controls who had the option to receive the inter-
vention after study participation.We think that the CDT concept may be further developed,
e.g. by selecting patients with evident points of interaction, such as stressors, high levels of dis-
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